Neurocrine Biosciences Inc. filings document the regulatory record of a commercial biopharmaceutical company developing and selling treatments for neurological, psychiatric, endocrine and immunological disorders. Its 8-K reports cover operating and financial results, product-sales disclosures, clinical or regulatory updates, material agreements, capital-structure matters and executive or employment-related governance events.
Proxy filings describe board matters, shareholder voting items, executive compensation, equity awards and pay-versus-performance disclosures. The filing record also includes formal disclosures related to INGREZZA, CRENESSITY and the company's pipeline, as well as risk, governance and transaction-related disclosure categories relevant to its public-company status.
Stephen A. Sherwin, a director of Neurocrine Biosciences Inc. (NBIX), reported a non-market transfer of 1,000 shares of the company's common stock on 09/02/2025 coded as a gift (transaction code G(1)). The form shows $0 as the price because no cash was received for the gifted shares. After the transaction, Mr. Sherwin beneficially owned 12,542 shares, held directly. The filing was executed by attorney-in-fact Darin Lippoldt and dated 09/03/2025. The Form 4 discloses this change in beneficial ownership and follows Section 16 reporting requirements.
Dr. Kevin Charles Gorman, a director of Neurocrine Biosciences (NBIX), exercised 106,322 non-qualified stock options with an exercise price of $35.99 and sold 106,322 resulting shares on 08/07/2025. The sales were effected by a broker under a Rule 10b5-1 trading plan adopted on February 24, 2025, at a weighted-average price of $126.4111 per share (sales ranged $124.80–$129.03). After the transactions, Dr. Gorman beneficially owns 514,596 shares; 514,596 of the outstanding shares are held by the Gorman and Blais Family Trust, of which he has voting and investment power. The options were granted on February 5, 2016, vested in monthly installments, and were due to expire on February 5, 2026. The disposition was effected pursuant to the pre-arranged 10b5-1 plan and the issuer’s policy prevents amendment of that plan after adoption.